Cochrane Abstracts
Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer New
Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer New is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Immune Checkpoint Inhibitors (anti PD‐1 or Anti PD‐L1) Plus Platinum‐etoposide Versus Platinum‐etoposide Alone for First‐line Treatment of Extensive Small Cell Lung Cancer New." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer_New. Accessed 06 February 2023.
Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer New. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer_New. Accessed February 6, 2023.
Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer New. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer_New
Immune Checkpoint Inhibitors (anti PD‐1 or Anti PD‐L1) Plus Platinum‐etoposide Versus Platinum‐etoposide Alone for First‐line Treatment of Extensive Small Cell Lung Cancer New [Internet]. In: Cochrane Abstracts. [cited 2023 February 06]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer New
ID - 433240
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer_New
DB - Evidence Central
DP - Unbound Medicine
ER -
